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Interleukin 32 expression in human 
melanoma
Helicia Paz1† , Jennifer Tsoi3,5†, Anusha Kalbasi1,4,6, Catherine S. Grasso5, William H. McBride4, 
Dörthe Schaue4, Lisa H. Butterfield7,8,9,10, Deena M. Maurer7, Antoni Ribas1,5,6, Thomas G. Graeber3,6 
and James S. Economou1,2,3,6*
Abstract 
Background: Various proinflammatory cytokines can be detected within the melanoma tumor microenvironment. 
Interleukin 32 (IL32) is produced by T cells, NK cells and monocytes/macrophages, but also by a subset of melanoma 
cells. We sought to better understand the biology of IL32 in human melanoma.
Methods: We analyzed RNA sequencing data from 53 in-house established human melanoma cell lines and 479 
melanoma tumors from The Cancer Genome Atlas dataset. We evaluated global gene expression patterns associated 
with IL32 expression. We also evaluated the impact of proinflammatory molecules TNFα and IFNγ on IL32 expression 
and dedifferentiation in melanoma cell lines in vitro. In order to study the transcriptional regulation of IL32 in these 
cell lines, we cloned up to 10.5 kb of the 5′ upstream region of the human IL32 gene into a luciferase reporter vector.
Results: A significant proportion of established human melanoma cell lines express IL32, with its expression being 
highly correlated with a dedifferentiation genetic signature (high AXL/low MITF). Non IL32-expressing differentiated 
melanoma cell lines exposed to TNFα or IFNγ can be induced to express the three predominant isoforms (α, β, γ) of 
IL32. Cis-acting elements within this 5′ upstream region of the human IL32 gene appear to govern both induced and 
constitutive gene expression. In the tumor microenvironment, IL32 expression is highly correlated with genes related 
to T cell infiltration, and also positively correlates with high AXL/low MITF dedifferentiated gene signature.
Conclusions: Expression of IL32 in human melanoma can be induced by TNFα or IFNγ and correlates with a treat-
ment-resistant dedifferentiated genetic signature. Constitutive and induced expression are regulated, in part, by cis-
acting sequences within the 5′ upstream region.
Keywords: Interleukin 32 (IL32), Melanoma dedifferentiation, IL32 transcriptional regulation, Immune infiltration, 
Myeloid polarization
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Background
Though first described in 1992 as NK4, interleukin 32 
(IL32) [1, 2] was recharacterized in 2005 as a proinflam-
matory cytokine differentially expressed in IL18 respon-
sive cells. Since then, its expression has been implicated 
in various pathologies, including rheumatoid arthritis, 
pathogen responses, atherosclerosis, and several malig-
nancies [3–12]. IL32 is broadly expressed in immune 
cells, including natural killer cells [13–15], T lympho-
cytes [16–18], macrophages, and dendritic cells [19, 20]. 
Functionally, IL32 can activate NF-κB and p38 mitogen 
activated protein kinase pathways and induce expres-
sion of proinflammatory cytokines including TNFα, IL8 
and CCL2. In addition to its presence in immune tis-
sues, IL32 expression can also be induced in human epi-
thelial tissues. IL32 is also expressed in a broad range 
of human epithelial cancers–gastric [3], lung [5], breast 
[4], colon [6–9], pancreas [10], and thyroid [11, 12]—as 
well as hematologic malignancies such as lymphoma and 
leukemia [16, 21]. IL32 expression in cancer is linked to 
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features associated with worse prognosis, including angi-
ogenesis, invasion, and metastasis [4].
However, the role of IL32 in human melanoma cells 
is less well understood. Initial studies suggested that 
IL32 expression was related to a more invasive, meta-
static phenotype marked by a loss of e-cadherin expres-
sion [22]. Others reported that IL32 isoforms alpha and 
gamma were highly enriched in PD-L1 expressing mela-
noma specimens [23].
Herein we report an unbiased analysis of IL32 expres-
sion in melanoma using RNA sequencing data from: [1] a 
large in-house panel of melanoma cell lines and [2] tumor 
tissues from The Cancer Genome Atlas (TCGA) dataset. 
IL32 expression correlated with a dedifferentiated pheno-
type which has been characterized by resistance to tar-
geted therapies, escape from immune recognition, and a 
high AXL/low MITF genetic signature [24–27]. Expres-
sion of IL32 in human melanoma can be transcription-
ally regulated in the context of a proinflammatory tumor 
microenvironment with either induced or constitutive 
IL32 expression strongly, but not invariably, correlating 
with a dedifferentiated genetic signature.
Methods
Cell culture
The human melanoma cell lines were established from 
patient biopsies. These cells were grown in RPMI 1640 
media supplemented with 10% FBS, 1% l-glutamine and 
1% penicillin/streptomycin/actinomycin D (Life Tech-
nologies, Grand Island, NY). Melanoma cell lines were 
treated with 1000  IU/mL TNFα and 100  IU/mL IFNγ 
(PeproTech US, Rocky Hill, NJ) for the indicated time 
points. M397 was cultured with recombinant 100  ng/
mL IL32α, -β, or -γ (R&D Systems, Minneapolis, MN) for 
7 days, with fresh IL32 being added every 2–3 days. Cells 
were counted using Trypan blue. Jurkat T lymphocytes 
were cultured in RPMI 1640 supplemented with 10% 
FBS.
Gene expression analysis
Gene expression FPKM values for the melanoma cell line 
panel was obtained from the Gene Expression Omnibus 
(GEO) accession number GSE80829. The hallmark gen-
eset for NF-κB and TNFα signaling (TNFA_SIGNAL-
ING_VIA_NFKB) was downloaded from the Molecular 
Signatures Database (MSigDB). Gene set enrichment 
analysis of the full ranked list of IL32 correlations was 
performed using the pre-ranked tool and the GO Biologi-
cal Process Ontology gene sets from MSigDB v6.1. Gene 
expression FPKM values of skin cutaneous melanoma 
tumor biopsies from The Cancer Genome Atlas (TCGA 
SKCM) was downloaded from the Genomic Data Com-
mons (portal.gdc.cancer.gov). For all analyses, FPKM 
values were log2 transformed with an offset of 1. Calcula-
tion of the enrichment overlap of the top 100 correlated 
genes with IL32 was performed using the MSigDB inves-
tigate gene sets tool (software.broadinstitute.org/gsea/
msigdb/annotate.jsp) and the hallmark gene sets.
Retroviral vectors
IL32 isoforms were cloned into an MSCV retroviral vec-
tor with a T2A-GFP using the HiFi DNA Assembly Clon-
ing Kit (NEB, Ipswich, MA). The retroviral vector was 
kindly provided by A. Ribas. Retroviruses were produced 
using GP2-293 cells (Clontech, Mountain View, CA) 
and human melanoma cells were transduced with IL32 
expressing retroviral vectors with 4ug/mL Polybrene. 
GFP positive cells were sorted 48  h after transduction. 
Cells maintained approximately 95% GFP positivity over 
the course of the experiment. IL32 expression was con-
firmed by real time PCR and Western blot.
Real time PCR
RNA was extracted using PureLink RNA Mini Kit (Ther-
moFisher, Waltham, MA) and cDNA was synthesized 
using the High-Capacity RNA-to-cDNA kit (Ther-
moFisher, Waltham, MA). Real time PCRs were per-
formed using the Applied Biosystems 7500 using the 
following primers designed using NCBI Primer-BLAST. 
GAPDH was used a housekeeping gene.
IL32 Primers:
IL32a Fwd: 5′-GAG GCA ACA GAT CCC CTG TC-3′.
IL32a Rev: 5′-GGC TCC GTA GGA CTT GTC AC-3′.
IL32b Fwd: 5′-TCT CTC GGC TGA GTA TTT GTGC-3′.
IL32b Rev: 5′-ATG ACC CAG CTC CAC TGA GA-3′.
IL32 g Fwd: 5′-TAC TTC TGC TCA GGG GTT GG-3′.
IL32 g Rev: 5′-TGG GTG CTG CTC CTC ATA AT-3′.
Differentiation gene set:
NGFR Fwd: 5′-TCA TCC CTG TCT ATT GCT CCA-3′.
NGFR Rev: 5′-TGT TCT GCT TGC AGC TGT TC-3′.
MLANA Fwd: 5′-GCT CAT CGG CTG TTG GTA TT-3′.
MLANA Rev: 3′-TTC TTG TGG GCA TCT TCT TG-5′.
MITF Fwd: 5′-ATC AGC AAC TCC TGT CCA GC-3′.
MITF Rev: 5′-GCC AGT GCT CTT GCT TCA GA-3′.
AXL Fwd: 5′-ACC TAC TCT GGC TCC AGG ATG-3′.
AXL Rev: 5′-CGC AGG AGA AAG AGG ATG TC-3′.
GAPDH Fwd: 5′-TGC ACC ACC AAC TGC TTA GC-3′.
GAPDH Rev: 5′-GGC ATG GAC TGT GGT CAT GAG-3′.
5′ rapid amplification of cDNA ends (RACE)
To determine the transcriptional start site of IL32, 5′ 
RACE was performed according the manufacturer’s 
directions for the SMARTer RACE 5′/3′ kit (Takara, 
Mountain View, CA). Briefly, RNA was isolated from the 
IL32 expressing cell line, M318, using NucleoSpin RNA 
II kits (Takara, Mountain View, CA). First strand cDNA 
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synthesis was done according the manufacturer’s direc-
tions. The 5′ RACE reaction using the following gene 
specific primer and a universal primer (Universal Primer 
Short, UPM, Takara) using 25 cycles of 94° for 30 s, 68° 
for 30 s, and 72° for 3 min. RACE products were run on 
an agarose gel and purified using the NucleoSpin Gel and 
PCR Clean-Up kit (Takara, Mountain View, CA). RACE 
products were cloned into the pRACE vector using the 
In-Fusion HD Cloning kit (Takara, Mountain View, CA) 
and sequenced using the M13F and M13R sequencing 
primers.
Luciferase constructs
The promoter region of IL32 were pcr’d from the Human 
BAC clone RP11 (RPC1-11 clone 473M20) using Pfusion 
DNA polymerase (NEB, Ipswich, MA). Promoter region 
greater than 3 kb were cloned into pGL3 using HiFi DNA 
Assembly Cloning Kit (NEB, Ipswich, MA). The pro-
moter regions were derived using the following primers.
− 10.5  kb Fwd: 5′-ACC GAG CTC TTA CGC GTG CTA 
GCC CGC AGG GAA GAA GGT GAG AGATG-3′.
− 7.5  kb Fwd: 5′-ACC GAG CTC TTA CGC GTG CTA 
GCC CCT CTT TAG CGG TGA GTG GGG-3′.
− 5.5  kb Fwd: 5′-ACC GAG CTC TTA CGC GTG CTA 
GCC CCA GTA GCT GGC TGT TTC GTG-3′.
− 2.5  kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTA 
GAA AGT AGA TGA GGC CAG-3′.
− 2 kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTA AAA 
CAG GGT ACA TAC AGT CTG -3′.
− 1.5  kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTG 
GAG TGC AGT GGC ACC AT-3′.
− 1.0  kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTG 
TTT GGC CCC AGG AAA CC-3′.
− 0.5  kb Fwd: 5′-CTA GCC CGG GCT CGA GAT CTC 
CCC AGC CAG CTG TCC CG-3′.
− 2.5  kb to − 0.5  kb Rev: 5′-CTC GAG CTC GAG TGG 
CGG CCA AAA GTT CAA GGAGC-3′.
− 10.5  kb to − 3  kb Rev: 5′-GAA TGC CAA GCT TAC 
TTA GAT CGC ATG GCG GCC AAA AGT TCA AG-3′.
Promoter regions were cloned into the SmaI/XhoI (less 
than − 3.0 kb) or HindIII (greater than − 3.0 kb) sites of 
pGL3 Luciferase reporter vector (Promega, Madison, 
WI). Promoter constructs were confirmed by Sanger 
sequencing. Promoter constructs were transfected into 
1.8–2 × 104 cells human melanoma cells in equal molar 
concentrations using Lipofectamine LTX with PLUS Rea-
gent (ThermoFisher, Waltham, MA). pGL4.74 (hRluc/TK, 
Promega, Madison, WI) was used for transfection nor-
malization. Firefly and Renilla luciferase expression was 
assessed 48 h after transfection using the Dual-Glo Lucif-
erase Assay system (Promega, Madison, WI). Cells were 
treated with 1000  IU/mL TNFα and 100  IU/mL IFNγ 
(PeproTech US, Rocky Hill, NJ) 24  h prior to assessing 
luciferase activity. All values were normalized to the pGL3 
empty vector control.
Myeloid cell polarization
PBMCs were collected using a ficoll gradient (Ficoll-Paque 
Plus, GE Healthcare) and monocytes were isolated by a 
CD14 positive selection (Miltenyi, Bergisch Gladbach, 
Germany). Monocytes were split into five experimental 
groups: (1) Negative Control (no cytokines), (2) GM–CSF 
(Sanofi) + IL-4 (Cell Genix) at 1000  U/ml, 3) Recombi-
nant IL32α (R&D Systems) at 100 ng/ml, 4) Recombinant 
IL32β (R&D Systems) at 100 ng/ml, 5) Recombinant IL32γ 
(R&D Systems) at 100  ng/ml, and cultured using Cell 
Genix Media to yield immature DCs at day 5. Immature 
DC were harvested and surface stained for flow cytom-
etry analysis. Cell surface markers were observed on the 
double positive, HLA-DR and CD86 population of cells. 
Antibodies used included CD80 FITC (BD, Clone L307.4), 
Mouse IgG1 FITC (Beckman Coulter PN IM0639U), 
CD86 Pe-Cy7 (BD, Clone FUN-1), HLA-DR PerCpCy5.5 
(BD, Clone G46-4), CD1B APC (BioLegend, Clone SN13), 
CD14 APC-Cy 7 (BD, Clone MφP9), CD68 BV 711 (BD, 
Clone Y1/82A), Mouse IgG2B BV 711 (BD, Clone 27-35), 
and Zombie Aqua Viability Dye BV 510 (BioLegend).
Statistical analyses
Gene expression bar graphs are shown as mean and 
standard differentiation. Gene expression was normal-
ized to GAPDH and expressed as Delta Ct values. Com-
parison between the reference control (untreated M397, 
M398, and M249) was performed with one-way analysis 
of variance (ANOVA, 95% CI) with a Dunnetts’ multiple 
comparisons test. All calculations were done using Prism 
software. p-values less than 0.05 were considered statis-
tically significant. For luciferase activity, data was nor-
malized to Renilla luciferase expression and fold changes 
were calculated against the pGL3 empty control vector. 
Error bars represent standard deviation.
Results
IL32 expression in human melanoma
We examined RNA sequencing data from a panel of 53 
established human melanoma cell lines derived from 
resected metastatic deposits [25, 26]. Across this data-
set, IL32 expression was detectable in a majority of the 
melanoma cell lines (Fig. 1a). IL32 expression in a sub-
set of melanoma cell lines was confirmed by real time 
PCR (data not shown). Immunohistochemical staining 
of IL32 in melanoma tissues, pulled from The Human 
Protein Atlas, indicates a range of expression within 
tumor samples (Additional file 1: Figure S1A) [28, 29]. 
However, it is notable that IL32 levels in melanoma are 
low relative to other tumor cell lines represented in the 
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NCI-60 Cancer Cell Line database or the Cancer Cell 
Line Encyclopedia (Additional file  1: Figures  S1B, C, 
respectively) [30, 31].
IL32 expression in human melanoma cell lines and tissues 
correlates with a dedifferentiated gene signature
We globally assessed IL32 co-expression patterns across 
the 53 cell lines by calculating the Pearson correlation 
between the expression of IL32 to all genes in the dataset. 
Among the top 75 anti-correlated genes with IL32 expres-
sion, we found classical melanocyte and pigment asso-
ciated genes such as MITF, TYR, PMEL, and MLANA 
(Fig. 1b). Gene expression scatterplots of MITF and TYR 
vs. IL32 show that melanoma cells with high IL32 expres-
sion are typically dedifferentiated, whereas differentiated 
melanoma are associated with absent or lower levels of 
0
1
2
3
4
5
M
26
3
M
29
7
M
30
8
M
39
5A
R
M
39
7
M
39
7A
R
M
39
8
M
23
0
M
24
9
M
41
2b
M
37
5
M
31
1
M
42
1
M
37
6
M
41
2a
M
23
8
M
26
2
M
40
6
M
24
5
M
20
7
M
28
5
M
40
3
M
24
9A
R
M
20
2
M
22
9
M
24
4
M
40
2
M
41
0
M
40
9A
R
M
39
9
M
24
3
M
41
7
M
42
3
M
41
6
M
40
8
M
36
8
M
39
5
M
40
9
M
40
7
M
29
6
M
22
9A
R P
B
M
37
0
M
25
5
M
42
0
M
25
7
M
38
1
S
bc
l2
M
23
3
M
23
8A
R
M
41
1
M
31
8
M
41
8
IL
32
a
0.0 −0.2 −0.4 −0.6
ZNF704
KLHL24
LRRC8B
MTUS1
TMCC2
KLF15
FAM69B
ANK2
NR4A1
PARL
NAT8L
ID4
SGK1
PDE3B
PPP1R3D
GPR137B
ESRP1
LONRF1
PCDH7
MITF
IGSF11
THNSL1
COX5A
HEY2
TYR
CELF2
ALKBH7
NRTN
ULK3
LAMA1
DSTYK
MAP6D1
LGALSL
BDH2
ST3GAL6
ETV5
APOE
MESDC1
ANKRD6
TMEM177
POLR3K
USP6NL
CTTNBP2
BEST1
MPPED2
ACP5
GJB1
CAPN3
TTYH2
PPFIA3
SCARB1
PRR5
CPN1
PFKM
CDK2
SLC24A5
WDR91
ANKRD44
TMC6
CEACAM1
PLEKHH2
CA14
PLA2G4A
IVNS1ABP
PTP4A3
MXI1
PDE8A
MLANA
PRTG
PMEL
TRIM63
TRAPPC2L
MFGE8
ATP7B
ATP1A1
Correlation
R= −0.578
p= 5.94e−06
2.5
5.0
7.5
0 2 4
IL32
M
IT
F
R= −0.572
p= 7.68e−06
0
4
8
0 2 4
IL32
TY
R
Melanocytic Genes
b c 0.0 0.2 0.4 0.6 0.8IL32
BIRC3
IL31RA
PDCD1LG2
HRH1
ROBO4
TNFRSF9
SCNN1G
ADRA1B
MAP3K14
WNT5B
ARNTL2
CSF2
IRAK2
CCL2
SH3RF1
TEKT1
GPR39
SLC14A1
TSLP
COL5A1
FOXC2
TRIM22
DCBLD1
DNAH5
PDGFC
TNIP1
ARHGEF28
SLC2A1
ITGA2
PAPPA
RRAS
CCDC85B
APOL3
BDKRB1
MYPN
TRAM2
FAM167A
ITGA3
BASP1
FLNB
IRF1
CARD10
CLCF1
NFKBIA
ZC3H12A
EDN1
AOX1
JUN
CALB2
LYZL6
SOCS5
TNFRSF12A
SDK1
RAB27B
MARCH4
XDH
ZMIZ2
CTSW
SYNJ2
EGFR
IL11
FADS3
IL6
JUND
COL13A1
PLEC
GLIS1
PVRL3
TMEM59L
CRISPLD2
SAMD9L
B3GALT5
TMEM154
SPIN1
Correlation
R= 0.735
p= 3.57e−10
0
2
4
6
0 2 4
IL32
B
IR
C
3
R= 0.626
p= 5.23e−07
1
2
3
4
5
0 2 4
IL32
IR
F1
NFκB and TNFα Genes
Fig. 1 IL32 is expressed in dedifferentiated melanomas. a Bar plot of log2 FPKM expression values across of panel of melanoma cell lines. b Bar 
plot showing the top 75 genes most correlated with IL32 expression. Genes highlighted in blue are melanocytic genes. (left) Scatterplot of log2 
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select anti-correlated genes and IL32 (right)
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IL32 (Fig. 1b). Furthermore, among the top 20 differen-
tially expressed genes in melanoma cell lines in the lowest 
quartile of IL32 expression (compared to top quartile), 
we identified enrichment of genes related to pigmenta-
tion and melanogenesis (TYR, MLANA, PMEL, TYRP1, 
DCT, and MITF; hypergeometric p-value = 7.9 × 10−15).
Previous studies have shown that a dedifferentiated 
MITF-low transcriptional state is associated with an 
NF-κB-high inflammatory cell state and that TNFα 
treatment can promote dedifferentiation [24, 27, 32]. 
Therefore, we investigated if genes positively corre-
lated to IL32 were involved in NF-κB or TNFα sign-
aling. To assess this, we obtained NF-κB and TNFα 
signaling genes from the well-curated hallmark collec-
tion [33]. Within the top 75 genes highly correlated to 
IL32 expression, we observed a strong enrichment for 
the NF-κB and TNFα hallmark genes (hypergeometric 
p-value = 2.1 × 10−11) (Fig.  1c). Scatterplots for repre-
sentative genes are shown in Fig.  1c. TNFα and IL32 
interactions have previously been described in the lit-
erature [16].
As a confirmatory step, we performed Gene Set 
Enrichment Analysis on the full ranked list of IL32 
expression correlations. Supportive of our earlier 
findings, the top gene sets highly enriched for IL32 
anti-correlation include pigmentation and metabolic 
gene sets, and the top most highly enriched for IL32 
expression include NF-κB and immune related gene 
sets (Tables  1, 2). Together, this suggests that IL32 is 
among several hundred melanoma genes whose expres-
sion is affected by exposure to these proinflammatory 
cytokines.
TNFα and IFNγ induced IL32 expression in general 
synchrony with dedifferentiation in melanoma cell lines
To evaluate if IL32 is induced with inflammatory sign-
aling, three non-IL32-producing melanoma cell lines 
(M397, M398, M249) were exposed to TNFα or IFNγ 
for 72 h (Fig. 2). We selected these three melanoma cell 
Table 1 Gene set enrichment analysis (GSEA) of genes correlated with IL32
Top ten enriched gene sets correlated with IL32 include NF-κB and immune-related gene sets
Name NES p-value FDR
q-value
1. Go I kappab kinase NF kappab signaling 2.461 < 0.001 < 0.001
2. Go cellular response to mechanical stimulus 2.456 < 0.001 < 0.001
3. Go positive regulation of chemotaxis 2.302 < 0.001 2.008E−03
4. Go tumor necrosis factor mediated signaling pathway 2.286 < 0.001 1.506E−03
5. Go modification by symbiont of host morphology or physiology 2.266 < 0.001 1.449E−03
6. Go response to mechanical stimulus 2.257 < 0.001 1.601E−03
7. Go positive regulation of response to external stimulus 2.223 < 0.001 2.745E−03
8. Go toll like receptor signaling pathway 2.217 < 0.001 2.698E−03
9. Go pattern recognition receptor signaling pathway 2.215 < 0.001 2.533E−03
10. Go NIK NF kappab signaling 2.212 < 0.001 2.280E−03
Table 2 Gene set enrichment analysis (GSEA) of genes anti-correlated with IL32
Top ten enriched gene sets negatively correlated with IL32 include pigmentation and metabolic gene sets
Name NES p-value FDR
q-value
1. Go developmental pigmentation − 2.619 < 0.001 < 0.001
2. Go melanocyte differentiation − 2.500 < 0.001 < 0.001
3. Go cellular respiration − 2.456 < 0.001 < 0.001
4. Go mitochondrial respiratory chain complex assembly − 2.446 < 0.001 < 0.001
5. Go oxidative phosphorylation − 2.400 < 0.001 < 0.001
6. Go pigmentation − 2.377 < 0.001 < 0.001
7. Go pigment cell differentiation − 2.374 < 0.001 < 0.001
8. Go aerobic respiration − 2.347 < 0.001 1.83E−04
9. Go tricarboxylic acid metabolic process − 2.251 < 0.001 6.51E−04
10. Go mitochondrial respiratory chain complex I biogenesis − 2.228 < 0.001 8.04E−04
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lines to observe the parallel impact of TNFα and IFNγ on 
IL32 and the melanoma differentiation state because they 
exhibited a low AXL/high MITF differentiated genetic 
signature. Both TNFα and IFNγ induced expression of 
the three predominant isoforms of IL32 (α, β, γ) in all 
three cell lines at varying levels. Overall, the impact of 
TNFα on IL32 expression was greater than the impact of 
IFNγ. Induction of IL32γ by TNFα was the most notable 
response in all three cell lines. The relative level of IL32 
isoform transcripts in these three cell lines, after TNFα 
induction, is generally lower than the constitutive expres-
sion in the two high IL32-producing, dedifferentiated cell 
lines M318 and M418 (Fig.  3a). For reference, we also 
evaluated IL32 transcript levels in the Jurkat T cell line, 
a recognized high IL32 expressing leukemia cell line. In 
general, with the exception of M318, the γ isoform is the 
most abundant and when induced by cytokine stimula-
tion has significantly higher and more prolonged induc-
tion (Figs. 2, 3a, b).
To test the parallel impact of IL32 induction with 
TNFα or IFNγ treatment on differentiation, we also 
evaluated expression of melanocytic markers MITF and 
MLANA, neural crest marker NGFR and the receptor 
tyrosine kinase AXL. A large and growing body of litera-
ture has shown the expression of AXL strongly inversely 
correlated with the expression of MITF, with a high AXL/
MITF ratio associated with therapy resistance [24, 25]. At 
baseline, these three melanoma cell lines exhibited a low 
AXL/high MITF differentiated genetic signature. In two 
of three cell lines (M397 and M398) we observed inver-
sion of the AXL/MITF ratio towards a dedifferentiated 
genotype in parallel with induction of IL32. However, 
one of three cell lines (M249) did not dedifferentiate in 
response to TNFα or IFNγ, despite induction of IL32. The 
lack of correlation between IL32 induction and inverted 
AXL/MITF ratio in M249 suggests that one event is 
not invariably accompanied by the other. Furthermore, 
enforced expression of recombinant IL32α, -β, or -γ in 
M397 did not impact expression of melanoma differenti-
ation genes MITF, AXL, NGFR or MLANA, strongly sug-
gesting that IL32 is not a causal or upstream event in the 
melanoma dedifferentiation process (Additional file  2: 
Figure S2).
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Proinflammatory cytokines TNFα and IFNγ induce IL32 
promoter activity in melanoma cell lines
We characterized the transcriptional regulation of IL32 
in human melanoma, both in constitutive and cytokine-
induced cells. CHIP-seq analysis of active enhancer and 
promoter elements, as defined by H3K4Me1, H3K27Ac, 
H3K3Me3 marks [34–37] in HUVEC and K562, cell 
lines known to express IL32, indicate the presence 
of regulatory elements 5′ relative to the IL32 trans-
lational start site (ATG) (Fig.  4a, ENCODE data set; 
University of California, Santa Cruz (UCSC) genome 
browser). Using 5′ RACE we determined the location 
of the transcription start site (TSS) in the IL32 posi-
tive cell line M318; two TSS were identified at − 464 bp 
and − 175  bp (chr16: 3,115,349 and chr16: 3,115,638) 
relative to the ATG (Fig. 4b). The Eukaryotic Promoter 
Database (EPD; http://epd.vital .it.ch) identified two 
putative IL32 promoters EPD NK4_1 and EPD IL32_1, 
which are − 558bps and − 221bps relative to the ATG 
(see “Discussion” Fig.  4b). Based on this information, 
we cloned various lengths of the IL32 5′ upstream 
genomic region (− 10.5, − 7.5, − 5.5, − 2.5, − 2, − 1.5, 
− 1, − 0.5) into a luciferase reporter construct; these 
constructs encompassed the putative EPD promot-
ers, both identified TSS sites, and the upstream (5′) 
ENCODE histone marks. These constructs were tran-
siently transfected into IL32 negative (M249, M397) 
and IL32 positive (M318) cell lines (Fig.  4d). Strong 
promoter activity was noted in the IL32 positive but 
not the negative cell lines, with the highest level in the 
− 10.5 and − 1.5 constructs. When both IL32 negative 
cell lines were exposed to TNFα or IFNγ for 24 h, there 
was a significant induction of promoter activity. TNFα 
consistently induced stronger IL32 promoter activ-
ity than IFNγ. M249, which cannot be dedifferentiated 
with TNFα or IFNγ, also showed strong IL32 promoter 
induction consistent with IL32 transcript expression. 
The promoter construct profiles were similar in both 
constitutive and induced settings.
IL32 in the melanoma microenvironment is associated 
with immune infiltration and melanoma dedifferentiation
Given the impact of TNFα and IFNγ on IL32 expres-
sion in melanoma cell lines, we investigated the expres-
sion of IL32 in the chemokine-rich melanoma tumor 
microenvironment using RNA sequencing data from 
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tumor biopsies as part of The Cancer Genome Atlas 
(TCGA) dataset. We observed strong Pearson correla-
tion coefficients between IL32 expression, found within 
the melanoma tumor and the surrounding microenvi-
ronment, and genes related to immune cell infiltration, 
such as CD3E (0.94), CD8A (0.89), IFNγ (0.75), and 
GZMB (0.86) (Additional file 3: Figure S3). Additionally, 
we observed a strong correlation between IL32 expres-
sion and several checkpoint receptors and ligands, such 
as PD-1 (0.87), PD-L1 (0.69), Tim-3 (0.82), Lag3 (0.85), 
and TIGIT (0.86) (Additional file 4: Figure S4). We also 
observed correlations between IL32 and genes related to 
other immune subsets, including myeloid cells (ITGAM, 
0.71; CD68, 0.61; CD14, 0.74), dendritic cells (ITGAX, 
0.71; ITGAE, 0.47) and B cells (CD19, 0.67). Consistent 
with this, the top 100 genes that correlated with IL32 
expression in the TCGA dataset were enriched with 
gene sets related to allograft rejection (hypergeometric 
p-value = 4.3 × 10−36), inflammatory response (hypergeo-
metric p-value = 3.3 × 10−10), and IFNγ signaling (hyper-
geometric p-value = 8.3 × 10−9).
In light of the impact of a proinflammatory microen-
vironment on melanoma differentiation, as well as the 
association between IL32 and dedifferentiation in mela-
noma cell lines, we investigated if this phenomenon was 
also present in the TCGA dataset. We observed a correla-
tion between IL32 expression in melanoma tumor biop-
sies with a high AXL/low MITF drug-resistant signature, 
consistent with data from melanoma cell lines (Addi-
tional file 3: Figure S3). However, IL32 did not inversely 
correlate with signature melanocyte genes (MLANA, 
PMEL, TYR ) as we observed in the cell line data (data not 
shown). Additionally, IL32 expression did not correlate 
with genes associated with disease progression, tumor 
cell invasion, and migration, such as CD155/PRV and 
MMP2 (Additional file 4: Figure S4).
IL32 isoforms have differential impact on myeloid 
polarization
IL32 from melanoma cells may influence non-melanoma 
cells in the tumor microenvironment, such as myeloid 
cells, which can play both pro- and anti-tumor roles 
depending on their phenotypic state. We preliminar-
ily assessed of the impact of IL32 on the polarization of 
myeloid cells. It has previously been reported that IL32γ 
induces the differentiation of monocytes into phagocytic 
macrophage-like cells (though they discordantly express 
CD14 and CD1a) [19]. However, the effect of IL32γ, or 
other IL32 isoforms (IL32α and IL32β), on myeloid cell 
polarization is not well understood. We observed that 
monocytes cultured with either IL32β or IL32γ express 
both CD68 and CD80, markers associated with M1 
proinflammatory macrophages thought to play an anti-
tumor role (Additional file  5: Figure S5). In contrast, 
exposure to IL-32α resulted in a CD68+ but CD80− 
population. Likewise, IL32β and IL32γ, but not IL32α, 
resulted in higher CD14 and CD1b expression.
Discussion
Human melanomas produce a number of cytokines 
generally associated with the immune system [38]. In 
an analysis of the RNA transcripts from 53 established 
melanoma lines, a significant proportion express IL32 
isoforms. Thus, we evaluated the biology underlying IL32 
expression in the context of melanoma both in cell lines 
and in melanoma tumor samples.
IL32 is found on human chromosome 16p13.3, is 
expressed in at least 6 splice variants (α, β, γ, δ, ε, ζ) and 
was originally isolated from activated natural killer and T 
cells [16]. Which isoforms are secreted as opposed to act-
ing intracellularly is still unresolved and hampered by an 
as of yet unidentified cell surface receptor [39, 40]. The 
γ isoform is the only isoform that has a leader sequence, 
is composed of all exons, is believed to be secreted, and 
believed to be the most biologically active [41]. A rodent 
IL32 homologue does not exist-raising the obvious ques-
tion as to whether or not this gene product is dispensa-
ble or redundant-but human recombinant and transgenic 
IL32 appears to be biologically active in mice [12, 42–44]. 
Despite these gaps in our knowledge, much of the pub-
lished literature on the biology of IL32 comes from 
experiments utilizing commercially available recombi-
nant protein, generally the α, β, and γ isoforms [1].
Several themes emerge regarding IL32 biology: (a) 
IL32 can modulate the production of various cytokines 
including IL1β [45], TNFα [46], IL6 [47], IL8 [8], and 
may activate cells of the immune system [15, 19]; (b) 
IL32 expression can be induced by various viruses and 
microbes [2, 20, 42, 48–51] and may play a role in anti-
viral immunity [52]; (c) IL32 may have direct effects on 
various cancer cells in vitro; [8, 9, 22, 47, 53, 54]; (d) IL32 
may play a role in tumor immunity [4, 7, 12, 14, 44]; [41]; 
and (e) IL32 has been associated with various inflamma-
tory diseases [43, 45], such as ulcerative colitis and rheu-
matoid arthritis [55]. It is also curious that, largely from 
immunohistochemistry studies, IL32 is expressed by a 
broad range of epithelial and in hematopoietic malignan-
cies and is generally correlated with aggressive biology, 
although no unifying mechanism has been identified.
In comparing IL32 expressing and non-expressing 
melanoma cell lines, we observed that IL32 expres-
sion in melanoma cell lines correlates with a high AXL/
low MITF ratio, a genetic signature which has been 
reported to be associated with a treatment-resistant, ded-
ifferentiation “invasive” phenotype. This dedifferentiation 
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phenotype results in reduced expression of melanocytic-
lineage antigens, which may also provide a mechanism 
for immune evasion [32]. Melanomas, which progress on 
MAPK inhibitor therapies, acquire this genetic signature 
of reduced MITF and RTK upregulation [25]. MITF con-
trols the expression of a broad range of genes in melano-
cyte-lineage cells that govern differentiation, migration, 
and proliferation [56–58]. The low MITF signature is reg-
ulated by receptor tyrosine kinases, including AXL [59].
The plasticity of these neural crest-derived cutaneous 
malignancies is underscored by the ability of an inflam-
matory signal—TNFα or IFNγ, for example—to effect a 
differentiated to dedifferentiated conversion in mela-
noma cell lines with only a 72 h in vitro exposure, a phe-
nomenon that reverses when the cytokine is removed 
from culture [26]. We found that TNFα and IFNγ, which 
promote a dedifferentiated melanoma phenotype, also 
induce IL32 expression in non-IL32 expressing mela-
noma cell lines by impacting activity at the promoter 
level.
Palstra et  al. recently reported that the DNA ele-
ment encompassing rs4349147 is a strong long distance 
enhancer essential for the expression of IL32 in CD4 
T cells located 10  kb 3′ of the IL32 promoter [52]. Jur-
kat cells are heterozygous for the rs4349147-A and 
rs4349147-G alleles. The A allele increases the expression 
of IL32α, generally viewed as anti-inflammatory, whereas 
the G allele promoted the expression of the proinflamma-
tory IL32γ and IL32β isoforms. These proinflammatory 
isoforms enhanced lymphocyte activation and suscepti-
bility to HIV infection. This report provides considerable 
insight into various observations on the biology of IL32 
isoforms. Two putative IL32 promoters have been identi-
fied using the Eukaryotic Promoter Database (http://epd.
vital -it.ch), which are depicted in Fig. 4. These two pro-
moters, at least in Jurkat cells, designated EPD NK4_1 
and EPD IL32_1, are thought to support the transcription 
of IL32γ and IL32α/β, respectively.
Our IL32 promoter constructs encompass both the 
identified EPD NK4_1 and EPD IL32_1 putative pro-
moter regions and extend 10.5  kb 5′ to the ATG. The 
luciferase activity driven by these constructs would then 
necessarily reflect constitutive and induced gene expres-
sion of all three isoforms, as well as the putative cis-acting 
elements residing within this 5′ upstream region. Palstra 
et al. performed formaldehyde-assisted isolation of regu-
latory elements (FAIRE) assays in Jurkat and a melanoma 
cell line (G361), which demonstrated significant increase 
in DNA accessibility in the region surrounding rs4349147 
in the former but not the latter cell line [52]. We there-
fore conjecture that this long-range enhancer may not 
play a role in melanoma IL32 transcription. In another 
IL32 promoter study using Akt-activated endothelial cell 
line constructs extending 2.5 kb 5′ to the ATG [60]; the 
difference in cell lines and activation signals precludes 
any meaningful comparison.
Given the impact of proinflammatory cytokines on 
IL32 expression, we investigated the IL32 expression 
in immunologically rich melanoma tumors using RNA 
sequencing data available in the TCGA dataset. IL32 
expression was highly correlated with a T cell dominant 
immune signature in these tumors, probably a result of 
immune cell IL32 production. We also observed a corre-
lation between IL32 expression, derived from tumor cells 
and the surrounding microenvironment, and a high AXL/
low MITF gene signature, as in the melanoma cell lines. 
However, we interpret this result cautiously because, 
unlike in the melanoma cell line dataset, IL32 expres-
sion in the melanoma tumor microenvironment did not 
inversely correlate with pigmentation or melanoma dif-
ferentiation genes such as MLANA, TYR or PMEL. Thus, 
the high AXL/low MITF signature may be a result of 
increased IL32 expression by infiltrating immune cells, 
rather than IL32 expressing dedifferentiated melanoma 
cells in the tumor microenvironment.
There is substantial evidence that IL32 induces dedif-
ferentiation of human monocytes towards a macrophage-
like phonotype with dendritic cell-like aspects. IL32 
exposed monocytes altered their morphology within 
3 days (flattening with extensive pseudopodia), which was 
accompanied by increased expression of CD1 and CD14 
[19]. These macrophage-like cells exhibited active phago-
cytic properties and were also induced to express TNFα, 
IL-1β and IL6. Our preliminary in vitro studies indicated 
that IL32, in an IL32β and IL32γ isoform specific manner, 
can modulate the polarization of myeloid cells toward 
an M1-like macrophage phenotype with costimulatory 
molecule expression, lending additional support for its 
impact in the tumor microenvironment. It is plausible, 
then, that IL32 is expanded within the microenvironment 
as a byproduct of the feedback loop between the anti-
tumor inflammatory response (marked by TNFα and 
IFNγ) and dedifferentiation of melanoma [23].
Conclusions
In summary, this study shows that a significant per-
centage of cell lines derived from metastatic melanoma 
express IL32. IL32 expression, which correlates with a 
dedifferentiated “invasive” genetic signature, can be 
induced by inflammatory molecules TNFα and IFNγ 
that modulate IL32 transcriptional activity at the pro-
moter level. IL32 expression by dedifferentiated tumor 
cells may contribute to a proinflammatory tumor 
microenvironment.
The remarkable advances in melanoma immuno-
therapy occasioned by the development of CTLA-4 
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and PD-1/PDL1 checkpoint inhibition underscores the 
importance of understanding potential contributions of 
melanoma-elaborated cytokines such as IL32 [61].
Additional files
Additional file 1: Figure S1. Expression of IL32 in human melanoma. 
(A) Immunohistochemistry analysis of IL32 expression in cutaneous 
melanoma in two patients with low and high IL32 expression, respectively 
(images and data acquired from The Human Protein Atlas, and Image 
available at https ://www.prote inatl as.org/ENSG0 00000 08517 -IL32/patho 
logy/tissu e/melan oma#img). Left panel is a cutaneous melanoma sample 
from a 73-year old woman (patient id: 2900). Right panel is a cutaneous 
melanoma sample from an 83-year old man (patient id: 2156). Staining 
was performed using BioLegend mouse anti-human IL32 monoclonal 
antibody (Cat # 513401) at a 1:4500 dilution after HIER antigen retrieval 
(pH = 6). (B and C) IL32 transcript expression across multiple different 
cancer lines organized by cancer type from the NCI-60 Cancer Cell Line 
database and the Cancer Cell Line Encyclopedia, respectively.
Additional file 2: Figure S2. Addition of recombinant IL32 does not 
impact melanoma cell line growth or differentiation. (A) Tumor growth 
over time in parental M397 melanoma cell line, compared to M397 treated 
with recombinant IL32α, -β or -γ. (B and C) Expression of melanoma dif-
ferentiation genes by quantitative RT-PCR at baseline or after treatment 
with TNFα, recombinant IL32α, IL32β, or IL32γ measured at day 3 (B) or 
day 7 (C).
Additional file 3: Figure S3. IL32 expression in the TCGA dataset. (A-B) 
Scatterplot of log2 FPKM expression values between IL32 and select 
immune genes (A) or between the ratio of AXL and MITF log2 FPKM 
expression values (B) in the melanoma TCGA dataset (n = 479).
Additional file 4: Figure S4. IL32, checkpoint receptors/ligand expres-
sion, and markers of disease progression in the TCGA dataset. Scatterplot 
of log2 FPKM expression values between IL32 and select checkpoint 
receptors/ligands, as well as, select markers of disease progression (MMP2 
and PVR).
Additional file 5: Figure S5. Expression of phenotypic markers on 
human monocytes after exposure to stimuli. CD14 + cells, from PBMC 
isolation, were cultured in the presence of GM-CSF + IL-4, Cell Genix 
Media, recIL32α, recIL32β, or recIL32γ for 5 days. The different treatments 
are displayed by using a gray scale. On day 5, the phenotype of the cells 
was assayed using flow cytometry analysis for various surface markers. 
GM-CSF + IL-4 and Cell Genix Media alone were as a positive and negative 
control, respectively. Cells were then assessed for surface expression of 
CD68, CD80, CD14, CD1B by flow cytometry. Frequency of positive cells is 
shown in the left panels, and mean fluorescence intensity is shown in the 
right panels. Statistical analysis was done using a one-way repeated meas-
ures ANOVA, using the GM-CSF + IL-4 treatment as a control. Each shape 
(circle, square, triangle) represents a different healthy donor. *P ≤ 0.05, 
**P ≤ 0.01, ***P ≤ 0.001.
Abbreviations
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